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Abstract
Background: Vitamin D deficiency is reported as a possible risk factor for the development of diabetes in several
epidemiologic studies. In this study, we investigated the frequency of 25-OH vitamin D deficiency in type 2 diabetes
mellitus and the relationship between 25-OH vitamin D deficiency and the prevalence of microvascular complications.
Methods: In this retrospective study, we evaluated the medical records of 557 patients with type 2 diabetes admitted
to the Endocrinology Outpatient Clinic from January to March 2010 and 112 healthy controls randomly selected from
individuals admitted to the hospital for a check-up and who had a laboratory result for serum 25-OH vitamin D
concentrations at screening. The levels of 25-OH vitamin D in patients with type 2 diabetes and the relationship
between 25-OH vitamin D deficiency and microvascular complications were investigated.
Results: No significant difference in serum 25-OH vitamin D concentrations was observed between the diabetic
and control groups. No correlation was observed between HbA1C and serum 25-OH vitamin D levels. Serum 25-OH
vitamin D levels were lower in diabetic patients with nephropathy, and patients not using any medication, i.e., those
treated with dietary changes alone, had a higher prevalence of nephropathy.
Conclusion: Vitamin D deficiency is more common in diabetic patients with nephropathy. When microvascular
complications were evaluated, vitamin D levels were found to be lower in patients in whom these complications
were more severe. Vitamin D deficiency is therefore associated with microvascular complications in diabetic patients.
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Background
Vitamin D deficiency is an important risk factor for
glucose intolerance [1]. Studies have shown impaired
insulin synthesis and secretion in animal models with
vitamin D deficiency; diabetes onset can be delayed with
1–25-OH vitamin D intake, and some specific studies
have reported that vitamin D deficiency contributes to
the etiology and progression of type 2 diabetes [2, 3]. 25-
OH vitamin D concentrations were found to be lower in
patients with type 2 diabetes with impaired glucose tol-
erance than in controls [4]. Vitamin D is a known sup-
pressor of renin biosynthesis, and vitamin D deficiency
has been associated with progression of chronic kidney
disease (CKD). Patients with type 2 diabetes and CKD
have an exceptionally high rate of severe 25-OH vitamin
D deficiency. This study investigates a possible relation-
ship between vitamin D status and microvascular com-
plications in patients with type 2 diabetes.
Methods
Patients with type 2 diabetes admitted to the Endocrin-
ology Outpatient Clinic from January to March 2010
owing to dietary or medication needs were included in
the study group, and healthy nondiabetic individuals
admitted to the hospital for a general check-up and
whose serum 25-OH vitamin D concentrations had been
requested formed the control group.
The vitamin D status of patients and controls was
screened retrospectively. Due to seasonal changes, only
patients whose vitamin D status was assessed during the
January to March period were included in the study. The
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25-0H vitamin D data were evaluated retrospectively, so
measurements for the other months could not be re-
trieved. Data were obtained from their medical records
and included detailed histories, physical examination
records, and laboratory findings (gender, age, height,
weight, body mass index (BMI), waist circumference,
fasting blood glucose, creatinine, HbA1c, low-density
lipoprotein (LDL) cholesterol, high-density lipoprotein
(HDL) cholesterol, triglycerides, and microalbumin
levels in 24-h urine). Glomerular filtration rate (GFR) is
the best overall index of kidney function. Normal GFR
varies according to age, sex, and body size, and declines
with age. The National Kidney Foundation recommends
using the CKD Epidemiology Collaboration (CKD-EPI)
Creatinine Equation (2009) to estimate GFR.
The medications received were stratified as diet alone,
oral hypoglycemic agents, or insulin. The relationships
between 25-OH vitamin D, HbA1c, microvascular com-
plications of diabetes (nephropathy, retinopathy, and
neuropathy), and type of treatment were investigated.
Patients with CKD, active infection, liver disease, pri-
mary hyperparathyroidism, macroalbuminuria, osteopor-
osis, serum creatinine level > 2 mg/dL, or those receiving
vitamin D or calcium supplements were excluded from
the study. For a diagnosis of nephropathy, patients were
defined as having microalbuminuria with 24-h urine
albumin content of 30–300 mg/day. For diagnosing
diabetic retinopathy (DR), all participants underwent an
ophthalmic examination by an experienced ophthal-
mologist. This examination consisted of funduscopy by
slit-lamp with 90 D lenses and indirect ophthalmoscopy.
DR was defined as the presence of one or more of the
following lesions: microaneurysms, blot or flame-shaped
hemorrhages, hard exudates, cotton-wool spots, or
evidence of laser treatment for DR at baseline. DR
was categorized as nonproliferative (NPDR) or prolif-
erative (PDR), determined by the presence of retinal
neovascularization.
Peripheral neuropathy was defined by abnormalities in
monofilament testing, performed with a Semmes-
Weinstein monofilament of 5.07/10 g, three times at
each site (dorsal between the base of digits 1–2; ventral
digits 1, 3, 5; metatarsal heads 1, 3, 5; medial and lateral
midfoot; and heel). If the patient missed perceiving the
filament more than once at one site, the test was consid-
ered abnormal at that site. If a subject did not perceive
the filament at two or more of the 10 sites, the test was
reported as abnormal. Vibration sensation was examined
using a diapason on the dorsum of the big toe. A 128-
Hz tuning fork was used to examine vibration percep-
tion at the dorsum of the interphalangeal joint of the
right hallux. The vibrating tuning fork was placed on the
interphalangeal joint and if nothing was felt, the score
was two points. When some vibration was sensed, the
still-vibrating tuning fork was immediately placed at the
dorsal wrist. When the vibration felt the same as that at
the hallux, the score was zero points, and when it felt
stronger, the score was one point.
The study group consisted of 557 patients who were
receiving dietary or medical treatment for confirmed
type 2 diabetes. The control group consisted of 112
healthy subjects who were admitted for check-up. The
study was conducted in accordance with International
Conference on Harmonization Good Clinical Practice
(ICH-GCP) guidelines, and the Declaration of Helsinki,
and approval for the study was granted by the Ethical
Committee of Ataturk Training and Research Hospital.
Laboratory analysis
Owing to hospital regulations, antecubital vein blood
sampling was performed between 8:00 and 10:00 a.m. on
all subjects, healthy or with diabetes, after a 12-h fast.
Fasting blood glucose was measured using a glucose oxi-
dase method (Roche Diagnostic GmbH). Total choles-
terol, HDL cholesterol, and triglycerides were measured
by enzymatic methods (Boehringer, Mannheim, Germany).
LDL concentrations were calculated via the Friedewald for-
mula. 25-OH vitamin D concentration and HbA1c were
measured by a high-performance liquid chromatography
(HPLC) method and by HPLC-ultraviolet (UV) detection,
respectively.
Statistical analysis
Statistical Package for Social Sciences (SPSS) 17.0 for
Windows software (SPSS Inc, Chicago, IL, USA) was
used for the data analysis. Continuous variables with a
normal distribution are presented as mean ± standard
deviation; non-normally distributed continuous variables
are presented as median (minimum to maximum); or-
dinal variables are presented as median and mode; and
nominal variables are presented as number and percent-
age. The normality of the distribution of the continuous
variables was evaluated using histograms and the one-
sample Kolmogorov-Smirnov test; distributions with
p > 0.05 were accepted as normally distributed. The
differences between normally distributed continuous
independent variables were evaluated with the inde-
pendent samples t test, and those without a normal
distribution were evaluated with the Mann–Whitney
U test. All hypotheses were examined using two-tailed
tests and p < 0.05 was used as the significance level.
The relationships between nominal variables were
evaluated using the Pearson chi-squared test and the
Fisher exact test; p < 0.05 was used as the significance
level. Statistical significance of risk factors for compli-
cations in diabetic patients, the results obtained via
univariate analysis were subjected to multivariate lo-
gistic regression.
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Results
The demographic characteristics of the subjects in the
study are shown in Table 1. There were 296 men in the
diabetic group and 45 in the control group. There were
261 women in the diabetic group and 67 in the control
group. Mean (±SD) age in the diabetic and control
groups was 55.2 ± 10.9 and 53.1 ± 12.5 years, respectively;
a statistically significant difference between the groups
was not observed (p = 0.07). Mean BMI in the diabetic
and control groups was 30.3 ± 5.5 and 29.8 ± 5.7 kg/m2,
respectively. The average duration of diabetes in the dia-
betic group was 5 years (0–20 years). The two groups were
similar in terms of age, height, weight, and BMI (Table 1).
HbA1c levels were higher in the diabetic group than in
controls, as expected (p < 0.001), and 25-OH vitamin D
concentrations did not differ between the two groups
(p = 0.302). Mean serum 25-OH vitamin D concentra-
tions were higher in men than in women (21.89 ± 8.74 vs
20.24 ± 8.53 ng/mL, respectively; p = 0.025).
Table 2 summarizes the prevalence of various
microvascular complications observed in both groups.
Microvascular complications were present in 172 of 555
patients (30.9 %). The mean 25-OH vitamin D con-
centrations in the groups with or without micro-
vascular complications were estimated to be 19.1 ± 8.1
and 22.0 ± 8.7 ng/mL, respectively; this difference was
statistically significant (p < 0.001). In the diabetic group,
nephropathy was observed in 91 patients (16.3 %). The
mean 25-OH vitamin D concentrations in the groups
with or without nephropathy were estimated to be
18.52 ± 8.2 and 21.6 ± 8.6 ng/mL, respectively. Pa-
tients with type 2 diabetes had lower total 25-OH
vitamin D concentrations than patients with any of the
microvascular complications (p < 0.001) or patients with
nephropathy (p = 0.002). In the diabetic group, retinopathy
was observed in 73 of 311 patients (23.4 %). Similar 25-
OH vitamin D levels were observed in both groups, with
or without retinopathy (20.0 ± 7.7 vs 19.7 ± 8.4 ng/mL;
p = 0.653). In the diabetic group, neuropathy was ob-
served in 89 of 311 patients (28.6 %). The mean 25-OH
vitamin D concentrations in the groups with or with-
out neuropathy were estimated to be 19.4 ± 7.9 and
20.0 ± 8.4 ng/mL, respectively; this difference was not
statistically significant (p = 0.617).
Table 3 presents a comparison of the patient and con-
trol groups where 25-OH vitamin D concentrations were
either above or below the threshold value of 20 ng/mL.
25-OH vitamin D levels <20 ng/mL and ≥20 ng/mL
were observed in 101 and 71 patients with microvascular
complications, respectively; the difference between the
groups was statistically significant (p < 0.001, χ2 = 17.3).
25-OH vitamin D levels of <20 ng/mL were observed in
53 of 84 patients with nephropathy; a statistically
significant difference was observed between the groups
(p < 0.001, χ2 = 12.7). 25-OH vitamin D levels of <20 ng/mL
were observed in 40 of 73 patients with retinopathy;
the difference between the groups was not statisti-
cally significant (p = 0.929, χ2 = 0.1). 25-OH vitamin D
levels of <20 ng/mL were observed in 49 of 89 patients
with neuropathy; the difference between the groups wasTable 1 Patient characteristics
Diabetes group Control group p value
(n = 557) (n = 112)
Gender (female/male), n 261/296 67/45 0.008
Age (years), mean ± SD 55.2 ± 10.9 53.09 ± 12.5 0.07
Height (m), mean ± SD 163.5 ± 9.7 163.1 ± 9.7 0.712
Weight (kg), mean ± SD 81.1 ± 15.1 78.8 ± 14.2 0.209
BMI (kg/m2), mean ± SD 30.3 ± 5.5 29.8 ± 5.7 0.381
HbA1c (%), mean ± SD 7.7 ± 1.7 5.6 ± 0.3 <0.001
25-OH vitamin D (ng/mL),
mean ± SD
21.1 ± 8.6 21.4 ± 11.8 0.302
GFR (mL/min per 1.73 m2),
mean ± SD
78.25 ± 21.5 80.1 ± 21.3 0.416
BMI body mass index, HbA1c glycated hemoglobin, GFR glomerular
filtration rate
Table 2 Mean 25-OH vitamin D levels in patients with type 2









Present 172 19.1 ± 8.1 <0.001
Absent 383 22.0 ± 8.7
Nephropathy Present 84 18.52 ± 8.2 0.002
Absent 466 21.6 ± 8.6
Retinopathy Present 73 20.0 ± 7.7 0.653
Absent 238 19.7 ± 8.4
Neuropathy Present 89 19.4 ± 7.9 0.617
Absent 222 20.0 ± 8.4
Table 3 Comparison of patients with type 2 diabetes with 25-OH
vitamin D levels below or above the 20 ng/mL threshold
25-OH vitamin D
<20 ng/mL ≥20 ng/mL p value
Microvascular
complications
Present 101 71 <0.001
Absent 152 231 χ2 = 17.3
Nephropathy Present 53 31 <0.001
Absent 196 270 χ2 = 12.7
Retinopathy Present 40 33 0.929
Absent 129 109 χ2 = 0.1
Neuropathy Present 49 40 0.873
Absent 120 102 χ2 = 0.1
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not statistically significant (p = 0.873, χ2 = 0.1). The in-
cidence of microvascular complications and nephropa-
thy was higher in the patients with type 2 diabetes
whose 25-OH vitamin D concentrations were <20 ng/mL
compared with patients whose 25-OH vitamin D concen-
trations were ≥20 ng/mL.
There was no correlation between HbA1c and serum
25-OH vitamin D levels (p = 0.095; r = −0.65), and HbA1c
levels were similar across groups where 25-OH vitamin
D concentrations were less than, equal to, or more than
20 ng/mL (p = 0.167, Z = 1.38).
Table 4 shows the 25-OH vitamin D levels and compli-
cation rates in groups stratified by antidiabetic treatment
received. In this study of 557 patients with type 2 dia-
betes, microvascular complications were observed in 6
of 18 (33.3 %) patients on diet only, 102 of 341 (29.9 %)
patients on oral antidiabetic drugs, and 138 of 198
(69.6 %) patients on insulin treatment. However, ne-
phropathy was significantly more prevalent in the group
treated by diet alone than in those receiving any type of
hypoglycemic medication (p < 0.001; χ2 = 51.4), and neur-
opathy was more prevalent in patients receiving insulin or
oral hypoglycemic treatments (p = 0.008; χ2 = 9.6).
Table 5 shows the 25-OH vitamin D levels and compli-
cation rates in patients with type 2 diabetes stratified by
gender.
The risk factors for complications in patients with type
2 diabetes, based on both univariate and multivariate
analyses, are shown in Table 6. Multivariate analyses
showed that HBA1C and 25-OH vitamin D were inde-
pendent predictors of complications in patients with
type 2 diabetes.
Discussion
The risk for diabetes and associated metabolic abnor-
malities increases with vitamin D deficiency [5–7].
Vitamin D status may influence the risk of developing
metabolic diseases such as type 2 diabetes, metabolic
syndrome, and insulin resistance [8].
Evidence from observational studies indicates inverse
association of circulating 25-OH vitamin D with risk of
death due to cardiovascular disease, cancer, or other
causes [9]. Vitamin D deficiency rates are also reported
to be higher among people with type 2 diabetes [10].
In their study of 825 patients undergoing dialysis,
Wolf et al. [11] observed a vitamin D deficiency rate
of 78 %, and this deficiency was associated with an
increased early mortality risk; when 25-OH vitamin D
was <10 ng/mL, the mortality rate increased 1.9-fold, and
with values between 10 and 30 ng/mL, the mortality rate
increased 1.4-fold. A meta-analysis by Pittas et al. [5] re-
ported that vitamin D deficiency was common in diabetic
patients, and diabetic complications could be delayed or
prevented by vitamin D supplementation. In contrast to
most reports, serum 25-OH vitamin D concentrations
did not differ between subjects with or without diabetes
in our study.
Selective vitamin D receptor activator paricalcitol effect-
ively reduce proteinuria in patients with type 2 diabetes
through inhibition of the renin-angiotensin-aldosterone
Table 4 25-OH vitamin D levels and rates of diabetes-related
complications by treatment received




(n = 18) (n = 341) (n = 198)
25-OH vitamin D (ng/dL),
(mean ± SD)
20.63 ± 10.2 21.4 ± 8.2 20.9 ± 8.5
Complications n (%) 6 (33.3) 102 (29.9) 138 (69.6)
Nephropathy 5 (27.8) 34 (9.9) 45 (22.7)
Neuropathy 0 (0) 42 (12.3) 47 (23.7)
Retinopathy 1 (9.1) 26 (7.6) 46 (23.2)
Table 5 25-OH vitamin D levels and rates of diabetes-related
complications by gender
Male Female p value
(n = 294) (n = 261)
25-OH vitamin D (ng/dL), (mean ± SD) 21.89 ± 8.7 20.24 ± 8.5 0.025
Complications, n (%) 103 (35) 69 (26.4) 0.034
Nephropathy 50 (17.2) 34 (13.1) 0.193
Neuropathy 50 (29.2) 39 (27.9) 0.802
Retinopathy 42 (24.6) 31 (22.1) 0.687
Table 6 Risk factors for complications in patients with type 2
diabetes, based on univariate and multivariate analysis
Risk factors p value Odds ratio 95 % CI
Univariate analysis




25-OH vitamin D 0.07 0.363–0.476
Multivariate analysis
Fasting blood glucose 0.307 0.998 0.993–1.002
HbA1c 0.006 1.275 1.073–1.516
LDL-cholesterol 0.661 0.999 0.994–1.004
Triglycerides 0.063 1.002 1.000–1.003
25-OH vitamin D 0.018 0.970 0.945–0.995
Age 0.400 1.009 0.993–1.025
BMI 0.639 0.991 0.955–1.029
Gender 0.081 1.447 0.955–2.191
BMI body mass index, HbA1c glycated hemoglobin, LDL low-density lipoprotein
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system (RAAS) [12]. Preclinical studies have shown that
vitamin D is renoprotective [13]. Paricalcitol therapy
did not affect plasma N-terminal probrain natriuretic
peptide concentration in patients with type 1 diabetes
and diabetic nephropathy; however, the urinary albumin
excretion rate was significantly lowered [14]. In a study
conducted in China, vitamin D treatment reduced
microalbuminuria in patients with type 2 diabetes and
nephropathy. RAAS is known to play a major role in
diabetic nephropathy, and vitamin D suppresses renin
release. Vitamin D deficiency increases albuminuria in
patients. Vitamin D replacement also has beneficial effects
on other diabetic nephropathy risk factors, such as hyper-
tension and hyperlipidemia [15, 16]. Vitamin D deficiency
is highly prevalent in patients with advanced CKD, but
diabetes, the most common cause of CKD, has also been
linked to low levels of serum 25-OH vitamin D. The
prevalence of 25-OH vitamin D deficiency (<20 ng/mL)
was 70.8 % in patients with diabetes-related CKD, 38.8 %
in patients with non-diabetic CKD, and 41 % in patients
with diabetes without advanced CKD. Low vitamin D sta-
tus is characteristically associated with advanced diabetic
nephropathy [17]. The potential mechanisms of renal
protection by vitamin D3 include inhibition of RAAS
and protection of the kidney from inflammation, fibro-
sis, and structural changes. In addition, vitamin D3
treatment is not associated with significant adverse ef-
fects, including gastrointestinal adverse effects, and
fluctuation of blood pressure. Vitamin D3 can amelior-
ate proteinuria and protect the kidney from injury in
patients with diabetic nephropathy. This renoprotective
effect is independent of blood pressure and glucose
reduction and does not increase adverse effects over
controls, even in combination therapy with angiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers [18].
In the NHANES study [19], insulin resistance, kidney
function, and vitamin D status of 14,679 patients were
assessed, and vitamin D deficiency was reported to be
associated with increased risks of microvascular and
macrovascular complications in patients with type 1 as
well as type 2 diabetes. In that study, 25-OH vitamin D
concentrations were lower in patients with diabetes mel-
litus and nephropathy compared to patients without
nephropathy. Decreased serum 25-OH vitamin D levels
in people with severely decreased kidney function is
independent of age, gender, ethnicity, and lifestyle vari-
ables known to affect vitamin D status, such as BMI,
physical activity, and intake of dairy foods and vitamin D
supplements. The relationship between serum 25-OH
vitamin D concentration at baseline and the incidence of
macrovascular (including myocardial infarction and
stroke) and microvascular (retinopathy, nephropathy,
neuropathy, and amputation) disease was analyzed. A
50 nmol/L difference in blood 25-OH vitamin D concen-
tration was associated with a 23 % (p = 0.007) change in
risk of macrovascular complications during the study;
low serum 25-OH vitamin D concentrations were associ-
ated with an increased risk of macrovascular and micro-
vascular disease events in type 2 diabetes [20].
Shebab et al. [21] showed that the onset of neuropathy
can be delayed by vitamin D treatment. Vitamin D defi-
ciency is more common in patients with distal symmet-
ric polyneuropathy, and neuropathic pain has been
reported to decline when the vitamin D deficiency is
corrected [22, 23]. Several studies showed a possible
association between vitamin D deficiency and diabetic
peripheral neuropathy (DPN) in patients with type 2 dia-
betes. A meta-analysis showed that vitamin D deficiency
was significantly associated with increased risk of DPN
in patients with type 2 diabetes (odds ratio [OR] 2.88;
95 % CI, 1.84–4.50; p < 0.00001). A meta-analysis of three
studies with adjusted estimates showed that vitamin D de-
ficiency was independently associated with increased risk
of DPN in patients with type 2 diabetes (OR 2.68; 95 % CI,
1.67–4.30; p < 0.0001) [24].
Vitamin D insufficiency is prevalent in patients with
type 2 diabetes mellitus and is associated with peripheral
neuropathy. However, there are few data regarding vita-
min D status in patients with cardiovascular auto-
nomic neuropathy. The mean circular resultant (MCR)
(39.5 ± 26.3 vs 27.6 ± 17.2; p < 0.01) and the expiration/
inspiration (E/I) ratio (1.21 ± 0.17 vs 1.15 ± 0.09; p < 0.01)
were lower in patients with 25-OH vitamin D insuffi-
ciency after controlling for age. This suggests that 25-OH
vitamin D insufficiency is associated with reduced para-
sympathetic function, with a stronger association in
younger patients with type 2 diabetes [25]. Studies of
patients with type 2 diabetes confirmed the relationship
between vitamin D deficiency and neuropathy incidence
as well as the severity of the symptoms caused by neur-
opathy. Recent studies also suggest a relationship be-
tween the incidence of plantar ulcers and vitamin D
deficiency [26]. However, no associations between neur-
opathy and 25-OH vitamin D were observed in our
study.
Several human studies have shown an inverse relation-
ship between vitamin D levels and several chronic condi-
tions associated with inflammation [27]. In the eye,
vitamin D receptors are expressed extensively in the
retina [28]. Therefore, vitamin D might prevent the de-
velopment and progression of DR as a result of its anti-
inflammatory and anti-angiogenic properties. There is
emerging evidence that DR is initiated and propagated
by inflammation and angiogenesis [29]. However, epide-
miologic studies evaluating the relationship between
vitamin D and DR are limited, although some clinic-
based case–control studies have proposed a possible
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association between the two variables [30]. Vitamin D
deficiency has been reported to be associated with in-
creased prevalence of DR among young patients with
type 1 diabetes; retinal vascular diseases were found to
be associated with the inflammatory and angiogenic ef-
fects of vitamin D deficiency [31]. An inverse relation-
ship was observed between the severity of retinopathy
and the circulating 1,25-(OH) 2 D3 concentration among
patients with type 2 diabetes, and a direct relationship
was observed between lower 25-OH vitamin D concen-
tration and the severity of the proliferative retinopathy
[32]. A total of 204 patients with type 2 diabetes were
subdivided into groups without diabetic retinopathy
(NDR, n = 110) and those with DR (n = 94). Logistic ana-
lysis confirmed that the duration of diabetes (OR 1.108;
p < 0.01), systolic blood pressure (OR 1.022; p < 0.05),
and HbA1c (OR 1.267; p < 0.05) were independently
associated with the risk of DR [33]. The study found a
sex-related difference in the association between serum
25-OH vitamin D levels and DR. Although men with
high serum 25-OH vitamin D levels had 63 and 85 %
lower risk of any DR and proliferative DR, respectively,
relative to those with the lowest levels after adjusting for
potential confounders, similar associations were not ob-
served in women. Moreover, a sex-related effect modifi-
cation was observed. The directions of the OR for any
DR and proliferative DR in women (OR1.58 and 1.99,
respectively) were opposite to those in men (OR0.37
and 0.15, respectively), which would explain the lack of
an overall association. These findings suggest that vita-
min D deficiency might be a significant risk factor for
any DR and proliferative DR in men but not in women
[34]. In one study, 1520 patients with type 2 diabetes
were recruited and divided into three groups according
to their fundus oculi results: no DR (n = 625, 41.12 %),
non-sight-threatening DR (n = 562, 36.97 %), and sight-
threatening DR (n = 333, 21.91 %). Vitamin D deficiency
was defined as serum circulating 25-OH vitamin D
level < 20 ng/mL. Vitamin D deficiency is an inde-
pendent risk factor for DR and sight-threatening DR;
the prevalence of sight-threatening DR doubles when
the serum 25-OH vitamin D level is <15.57 ng/mL
[35]. However, we found no significant associations
between the vitamin D status and retinopathy in our
present study.
Conclusions
Previous reports have shown that a low concentration of
serum 25-OH vitamin D increases the risk of developing
diabetes later in life and is also associated with an in-
creased risk of diabetic microvascular complications,
though our study only showed such associations for
nephropathy. The vitamin D status of patients with
diabetes should be considered during their regular
follow-up, and supplementation should be provided
to those at risk of deficiency.
Limitations of the study
Because this was as a retrospective study, all patient data
could not be fully retrieved. There is a need for pro-
spective or controlled studies with larger sample sizes
where vitamin D replacement and complication regres-
sions are followed and where the impact of the vitamin
D levels on blood glucose regulation is observed.
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